Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study

[1]  William M. Lee,et al.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.

[2]  Hirokazu Takahashi,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011, Journal of gastroenterology.

[3]  N. Enomoto,et al.  Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  N. Enomoto,et al.  Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection , 2010, Hepatology.

[5]  T. Suda,et al.  Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2009, Digestive Diseases and Sciences.

[6]  Y. Imai,et al.  Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  T. Arakawa,et al.  Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. , 2009, Journal of hepatology.

[8]  William M. Lee,et al.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.

[9]  Yoshiyuki Suzuki,et al.  Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. , 2007, Journal of medical virology.

[10]  Yoshiyuki Suzuki,et al.  Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C , 2007, Journal of medical virology.

[11]  T. Ide,et al.  A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP , 2006, Digestive diseases and sciences.

[12]  Raymond T Chung,et al.  Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. , 2005, Journal of hepatology.

[13]  E. Heathcote,et al.  Prevention of hepatitis C virus-related hepatocellular carcinoma. , 2004, Gastroenterology.

[14]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[15]  T. Liang,et al.  Pathogenesis of hepatitis C-associated hepatocellular carcinoma. , 2004, Gastroenterology.

[16]  T. Sakurai,et al.  Lens culinaris agglutinin-A-reactive alpha-fetoprotein as a marker for liver atrophy in fulminant hepatic failure. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  M. Yano,et al.  Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[18]  T. Honda,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy. , 2002, Hepato-gastroenterology.

[19]  X. Forns,et al.  Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. , 2001, Journal of hepatology.

[20]  M. Bernardi,et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. , 2001, Journal of hepatology.

[21]  P. Andreone,et al.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. , 2001, Journal of hepatology.

[22]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[23]  T. Okanoue,et al.  Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. , 1999, Journal of hepatology.

[24]  N. Hayashi,et al.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.

[25]  G Realdi,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). , 1997, Journal of hepatology.

[26]  M. Mizokami,et al.  New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a , 1997, Journal of clinical microbiology.

[27]  G. Marchesini,et al.  Efficacy of a surveillance program for early detection of hepatocellular carcinoma , 1996, Cancer.

[28]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[29]  S. Fujiyama,et al.  Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. , 1995, Hepato-gastroenterology.

[30]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[31]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[32]  K. Taketa.  α‐fetoprotein: Reevaluation in hepatology , 1990 .

[33]  E. Schiff,et al.  Hepatitis C–associated hepatocellular carcinoma , 1990, Hepatology.

[34]  M. Houghton,et al.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA , 1989, The Lancet.

[35]  J. Bruix,et al.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS , 1989, The Lancet.

[36]  E. Feller,et al.  Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. , 1978, Gastroenterology.

[37]  T. Waldmann,et al.  α-Fetoprotein in Nonneoplastic Hepatic Disorders , 1975 .

[38]  T. Waldmann,et al.  alpha-fetoprotein in noneoplastic hepatic disorders. , 1975, JAMA.

[39]  E. Ruoslahti,et al.  Normal and increased alpha-fetoprotein in neoplastic and non-neoplastic liver disease. , 1972, Lancet.

[40]  Mcgavi Dd.  RESPIRATORY DISEASE IN FLAX WORKERS. , 1965 .

[41]  Williams Jt,et al.  ROYAL COLLEGE OF PHYSICIANS. THE NEW BUILDING. , 1964, Lancet.

[42]  池田 一毅.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma : a prospective study , 2012 .

[43]  Hirokazu TakahashiToshihiko,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011 .

[44]  K. Migita,et al.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus , 2010, Journal of Gastroenterology.

[45]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[46]  J. Manson,et al.  Prospective Study of , 2007 .

[47]  L. Benvegnu'.  Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. , 1998, Lancet.

[48]  K. Taketa.  Alpha-fetoprotein: reevaluation in hepatology. , 1990, Hepatology.